PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: tourism industry

Treating Hyperkalemia: Avoid Additional Harm When Using ...

Treating hyperkalemia : Avoid Additional Harm When Using Insulin and Dextrose | Advisory Page 1 of 11. Pa Patient Saf Advis 2017 Sep;14(3). Treating hyperkalemia : Avoid Additional Harm When Using Insulin and Dextrose Authors Staley Lawes, PharmD, BCPS, FISMP. Patient Safety Analyst Michael J. Gaunt, PharmD. Sr. Medication Safety Analyst Matthew Grissinger, RPh, FISMP, FASCP. Manager, Medication Safety Analysis Pennsylvania Patient Safety Authority Corresponding Author Matthew Grissinger Abstract hyperkalemia is a fairly common, potentially life-threatening electrolyte disturbance encountered in hospitalized patients. Treatment of hyperkalemia with insulin and dextrose, without implementing clear protocols and error- reduction strategies, can lead to hypoglycemia and other patient harm.

available insulin products (e.g., humul%, novol%), Kayexalate , and polystyrene. One hundred ninety-eight events met the inclusion criteria and were included in the final analysis.

Fullscreen Download
Loading..

Tags:

  Kayexalate, Hyperkalemia

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of Treating Hyperkalemia: Avoid Additional Harm When Using ...

Documents from same domain

Opioid Knowledge Self-Assessment

patientsafety.pa.gov

Opioid Knowledge Self-Assessment Healthcare facilities can use this assessment for practitioners who prescribe, dispense, and/or administer opioid products ...

  Assessment, Opioid, Self, Knowledge, Opioid knowledge self assessment

Letter to the Editor: Preventing Air Embolism with PICC ...

patientsafety.pa.gov

letter to the editor: preventing air embolism with picc line removal I read with interest your article “Reducing Risk of Air Embolism Associated with Central Venous Access Devices” in the Pennsyl-

  With, Letter, Preventing, Editor, Letter to the editor, Ccpi, Embolism, Preventing air embolism with picc

Strategic Plan 2017-2020 - Patient Safety Authority

patientsafety.pa.gov

Strategic Plan During 2016, the Pennsylvania Patient Safety Authority Board of Directors and staff engaged in a third strate- ... Strategic Plan 2017–2020 VISION Safe healthcare for all patients MISSION Improve the quality of healthcare in Pennsylvania by collecting and

  2017, Strategic, Plan, 2200, Strategic plan, Strategic plan 2017 2020

PATIENT SAFETY: COLOR BANDING Standardization and ...

patientsafety.pa.gov

Color-banding policy will need to be reviewed and approved. Hospitals need to review their respective forms for need of modifications (pt. ed, assessments, etc.) ... • Color Code – Intent of Specific Colors • Authority for Application of band • Process for Band Confirmation • Inter-Dept./Agency Communication

  Policy, Code, Color, Color code

Confirming Feeding Tube Placement: Old Habits Die Hard

patientsafety.pa.gov

More Reliable Methods to Verify Feeding Tube Placement Radiographic Confirmation of Nasogastric Tube Placement The gold standard for nasogastric feeding tube placement is radiographic confirmation with a chest x-ray. pretations by nonradiologists: The gold standard for nasoenteric feeding tube placement is radiographic confir-

  Tubes, Placement, Nasogastric, Nasoenteric, Tube placement, Nasogastric tube placement

The Beers Criteria: Screening for Potentially ...

patientsafety.pa.gov

hepatic clearance of many drugs, such as diazepam, amitriptyline, and chlordiazepoxide, carried out by the cytochrome P-450 system often diminishes with age. Overall, the clearance of drugs metabolized by the liver is typically decreased 30 to 40% in the elderly. Renal size and renal blood flow also decrease signifi-cantly with age.

  Learn, Hepatic

Safety in Using Promethazine (Phenergan)

patientsafety.pa.gov

©2007 Pennsylvania Patient Safety Authority Page 1 Produced by ECRI Institute & ISMP under contract to the Patient Safety Authority Patient Safety Advisory F irst approved by the U.S. Food and Drug Ad-ministration (FDA) in 1951, promethazine (Phenergan) is a medication in common use today. However, despite its familiarity, its use is not with-

  Using, Safety, Phenergan, Promethazine, Is not, Safety in using promethazine

PATIENT SAFETY AUTHORITY AND DEPARTMENT OF HEALTH

patientsafety.pa.gov

12. A mid-procedure change in the plan of care in response to new information discovered during the procedure does not constitute an injury. 13. Additional healthcare services: a. Healthcare services provided to prevent an injury from occurring are excluded from this term for the purpose of Serious Event determinations. b.

  Safety, Procedures

Brochure Medical Records - Pennsylvania Patient Safety ...

patientsafety.pa.gov

record. In the future, when medi-cal records are requested by other providers, your provider must include his denial of your request to amend the medical record as well a copy of your statement of disagreement. It should not take more than 90 days to amend your medical records. If the request is accepted,

  Record, Medi, Cal records

Retained Surgical Items: Events and Guidelines Revisited

patientsafety.pa.gov

and the Association of periOperative Registered Nurses published guidance for preventing RSIs, including minimizing distractions and participating in team-work training. The Joint Commission speaks to the role of weak or absent organizational leadership as reasons for the continuance of RSIs. (Pa Patient Saf Advis 2017 Mar;14[1]:27-35.)

  Time, Nurse, Surgical, Association, Registered, Perioperative, Detainer, Association of perioperative registered nurses, Retained surgical items

Related documents

All of the following medications are gluten free unless ...

glutenfreedrugs.com

Kayexalate Keflex Kemadrin Keppra (all strengths) Ketek Ketoprofen XR (Andrx) Kirkman (all products are GF) Klor-Con Lacrisert Lactaid Fast Act Chewables- No gluten or any carbohydrates Lactaid Fast Act Caplets- No gluten or any carbohydrates Lamictal Lamisil Lamprene Lanoxin Lasix Leflunomide (Apotex, Sandoz) Lescol / XL Lessina-28 Leucovorin

  Free, Gluten, Gluten free, Kayexalate

MAINTENANCE FLUID REQUIREMENTS RESUSCITATION …

anesthesia.ucsf.edu

Kayexalate 1-2 g/kg PO/PR ENDOCARDITIS PROPHYLAXIS GUIDELINES AHA 2007 At risk conditions 1. Presence of prosthetic valve or prosthetic material used for cardiac valve repair 2. A history of endocarditis 3. A heart transplant with abnormal heart valve function 4. Congenital heart disease: Uncorrected or palliated cyanotic CHD, completely repaired

  Kayexalate

Management of severe hyperkalemia - EMCrit

emcrit.org

(Kayexalate, Kionex) 15–30 g in 15–30 mL (70% sorbitol orally) 2 hrs 4–6 hrs Variable efficacy intestinal necrosis Hemodialysis Immediate 3 hrs Arrhythmias (?) IV, intravenously. Crit Care Med 2008 Vol. 36, No. 12 3247. agent is the gluconate salt, since it is less

  Management, Severe, Kayexalate, Hyperkalemia, Management of severe hyperkalemia

Lab Values: Interpreting Chemistry and Hematology for ...

lms.rn.com

Mar 30, 2012 · • Kayexalate: This is a cation-exchange resi n, Na+ based (An ion-exchange resin that has the ability to exchange positive ions in the stationary phase with positive ions in solution) • Calcium administration: Used to decrease the antagonistic effect …

  Chemistry, Kayexalate

Hyperkaliémie

www.srlf.org

Résines échangeuses d’ions KAYEXALATE® PO 15-30g / 4-6H, ou en lavement 50-100 g gardé 30-60 min Facteurs pronostiques Urgence métabolique absolue si : K+ > 7 mmol/L et/ou signes ECG. Indication Hémodialyse en urgence. En attente de dialyse = sels de calcium + 1 traitement hypokalièmiant par transfert du K+ en intracellulaire.

  Kayexalate

Kayexalate (Sodium Polystyrene Sulfonate)

products.sanofi.ca

KAYEXALATE Prescribing Information Page 2 of 12 DESCRIPTION KAYEXALATE (sodium polystyrene sulfonate) is a cream or light brown fine powder of sodium polystyrene sulfonate. KAYEXALATE is a cation-exchange resin prepared in the sodium phase, with an in vivo exchange capacity of approximately 1 mmol (in vitro

  Kayexalate

Best Practices in Managing Table 3. 6 HYPERKALEMIA

www.kidney.org

TREATMENT OF HYPERKALEMIA IN CKD. REFERENCES . Table 3. 30 East 33rd Street. New York, NY 10016 800.622.9010. www.kidney.org. This publication has been sponsored and developed in collaboration with Relypsa, Inc.

  Kidney

Related search queries

Gluten free, KAYEXALATE, Gluten, Management of severe hyperkalemia, Chemistry